Form 8-K - Current report:
SEC Accession No. 0001104659-24-130002
Filing Date
2024-12-19
Accepted
2024-12-19 08:21:17
Documents
17
Period of Report
2024-12-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2431560d1_8k.htm   iXBRL 8-K 27616
2 EXHIBIT 10.1 tm2431560d1_ex10-1.htm EX-10.1 316702
3 EXHIBIT 99.1 tm2431560d1_ex99-1.htm EX-99.1 25617
4 EXHIBIT 99.2 tm2431560d1_ex99-2.htm EX-99.2 15830
8 GRAPHIC tm2431560d1_ex99-2img002.jpg GRAPHIC 4494
  Complete submission text file 0001104659-24-130002.txt   661103

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20241219.xsd EX-101.SCH 3018
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20241219_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20241219_pre.xml EX-101.PRE 22361
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2431560d1_8k_htm.xml XML 3808
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 241561048
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)